The first Oral broad spectrum anti-fungal.

trademark

Nizoral

(ketoconazole)

Superficial Fungal Infections.

NIZORAL* is a new *Oral* anti-fungal agent effective against both dermatophyte and yeast infection of the skin and scalp.

Vaginal Candidosis.

NIZORAL* offers a simple, effective *Oral* therapy to aid patient compliance.

Systemic Fungal Infections.

NIZORAL* is a uniquely convenient and well tolerated treatment. It is also effective in prophylaxis for immuno-compromised patients.

Prescribing Information Presentation: White, flat, half scored uncoated tablets marked "Janssen" on one side and K/200 on the reverse. Each contains ketoconazole 200mg. **Uses:** Nizoral* is an orally active antimycotic for the treatment in adults, of vaginal candidosis; superficial and systemic mycoses including dermatophyte and yeast infection of the skin, hair and nails, yeast infection of the mouth and GI tract. Also maintenance treatment in systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children: systemic mycoses and severe local infections where previous topical treatment has failed. **Side effects, Precautions, Contra-indications:** Contra-indicated in pregnancy. For maximal absorption Nizoral* should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H_2 blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral* Nausea, skin rash, headache and pruritus occasionally observed. Alterations in liver function tests have occurred in patients on ketoconazole; these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long term therapy e.g. for onychomycosis. If a patient develops jaundice or any symptoms suggestive of hepatitis treatment with ketoconazole should be stopped. **Dosage: Adults:** vaginal candidosis – 200mg morning and evening for 5 days, superficial and systemic mycoses, prophylactic treatment – 200mg once daily increased to 400mg daily if required. **Children:** 50 or 100mg depending on body weight (approximately 3mg/kg). **Product Licence No.** PL0242/0083. **Basic NHS Cost:** 10 tablets £4.90, 30 tablets £14.26 (correct at time of printing).

Further information is available from:– **Janssen Pharmaceutical Limited,** Janssen House, Chapel Street, Marlow, Bucks. SL7 1ET. *trademark



Septrin Assurance

Prescribing Information

Indications Sensitive bacterial infections of the lower respiratory, urinary and genital tracts, sinusitis, otitis media, skin infections, septicaemia, typhoid and paratyphoid fevers, and other infections caused by sensitive organisms.

Dosage Septrin Forte Tablets. Adults and children over 12 years: 1 forte tablet twice daily. Maximum dosage for particularly severe infections 1½ forte tablets twice daily. In acute infections Septrin should be given for a minimum of five days or until the patient has been symptom-free for two days.

Contra-indications Septrin is contra-indicated in patients with marked liver parenchymal damage, blood dyscrasias or severe renal insufficiency. Septrin should not be given to patients hypersensitive to sulphonamides, trimethoprim or co-trimoxazole; should not be given during pregnancy or to neonates.

Precautions In renal impairment a reduced dosage is indicated and an adequate urinary output should be maintained. Regular blood counts are necessary whenever long-term therapy is used. Caution is advised in patients with folate deficiency. Care should be taken when giving Septrin to patients receiving oral anticoagulants of the coumarin group, pyrimethamine or sulphonylureas.

Adverse Reactions Occasionally, nausea, vomiting, glossitis and skin rashes may occur with normal doses and, very rarely, haematological reactions.

Presentation Septrin Forte Tablets each contain 160 mg Trimethoprim BP and 800 mg Sulphamethoxazole BP. PL3/0121.

Septrin* Forte 1b.d.
co-trimoxazole

Further information is available on request.
Wellcome Medical Division
The Wellcome Foundation Ltd., Crewe, Cheshire

Wellcome

*Trade Mark

Published by the Proprietors, THE BRITISH MEDICAL ASSOCIATION, Tavistock Square, London WC1H 9JR, and printed in Great Britain by George Pulman and Sons Limited of London and Bletchley, Typesetting by Bedford Typesetters Limited, Bedford, and TypeMatters (London) Ltd., London E.C.1. Registered as a Newspaper

Need epilepsy make him different?



Tegretol®
carbamazepine

for the child with epilepsy

Indications Epilepsy (grand mal and temporal lobe). **Dosage in epilepsy** Use a gradually increasing dosage scheme, adjusting to patient's needs. Adults: 100-200mg once or twice daily, increasing slowly up to 800-1,200mg daily; in some cases 1,600mg daily may be necessary. Children: up to 1 year old, 100-200mg daily; aged 1-5 years, 200-400mg daily; aged 5-10 years, 400-600mg daily; aged 10-15 years, 600-1,000mg daily. It may be helpful to monitor plasma drug levels: optimum therapeutic range is 3-10μg/ml (13-42μmols/l). **Side-effects** Dizziness and diplopia (usually dose-dependent), less frequently drowsiness, dry mouth, diarrhoea, nausea and vomiting. Generalised erythematous rash, disappearing on cessation of therapy. Isolated reports of oedema, hyponatraemia, exfoliative dermatitis, leucopenia, thrombocytopenia, agranulocytosis, aplastic anaemia, cholestatic jaundice and acute renal failure. Blood count should be checked in early stages of treatment. **Precautions** Caution in patients taking oral anticoagulants or requiring oral contraception. In pregnancy, potential benefits of Tegretol must be weighed against potential hazards. Do not administer with, or within two weeks of cessation of, MAOI therapy. In rats treated with carbamazepine for two years, incidence of liver tumours increased (no evidence of significant bearing on the therapeutic use of the drug). Serum folic acid levels should be observed during anticonvulsant therapy. **Contra-indications** Previous drug sensitivity to Tegretol. Do not administer to patients with atrioventricular conduction abnormalities unless paced. **Packs** Tablets of 100mg (PL0001/5027) basic NHS price £2.99 per 100, £14.40 per 500; tablets of 200mg (PL0001/5028) £5.56 per 100, £26.78 per 500; tablets of 400mg (PL0001/0088) £10.92 per 100; syrup 100mg/5ml (PL0001/0050) £5.34 per 300ml bottle. Full prescribing information is available on request from Geigy Pharmaceuticals, Horsham, West Sussex.

Geigy